E ach year in the United States alone, there are >1.5 million hospital admissions for acute coronary syndromes (ACSs), 1 whereas in Europe, the estimated annual incidence of ACSs is thought to vary between 1 per 80 and 1 per 170 of the population. 2 Despite widespread use of proven treatment approaches, patients with ACS remain at considerable risk for subsequent cardiovascular events. 3, 4 The finding that culprit lesion revascularization after ACS reduces the relative risk of mid-to-long-term cardiovascular events by only 20% 3 suggests that many of these events are likely to arise from sites remote to the original culprit lesion. 5,6 Such observations underscore the systemic nature of atherosclerosis and plaque instability. 7-9 Therefore, systemic antiatherosclerotic therapies may add considerably to the local treatment of the culprit lesion in preventing recurrent events in patients with ACS.
whereas European guidelines advocate lowering low-density lipoprotein cholesterol (LDL-C) levels with statins to either <70 mg/dL or to at least achieve a 50% reduction from baseline levels in patients considered to be at high cardiovascular risk. 11 Indeed those receiving intensive versus moderate statin therapy after ACS seemingly derive the greatest clinical benefit. [12] [13] [14] [15] [16] Yet despite the effectiveness and established tolerability of potent statin therapy, 17 there remains a considerable gap between guideline recommendations and real-world practice for treating ACS. Not only are a majority of patients with ACS not prescribed intensive statin therapy 18 but also of those prescribed statins, few achieve LDL-C levels of ≤70 mg/dL. 19 Although there seems to be an early clinical benefit when initiating intensive versus moderate statin therapy acutely after ACS, [20] [21] [22] to date no study has documented the longer term antiatherosclerotic efficacy of this treatment approach in the ACS population. Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN; ClinicalTrials.gov number, NCT000620542) was the largest imaging trial comparing the antiatherosclerotic efficacy of 2 of the most potent statin regimens, by measuring the change in coronary atheroma volume on serial intravascular ultrasonography (IVUS). 23 No appreciable difference of the primary efficacy end point of change in percent atheroma volume (PAV), safety, or clinical event rates was found between the 2 treatment groups. Thus, we undertook a post hoc analysis of the total SATURN cohort to ascertain that the long-term (24 months) antiatherosclerotic efficacy of maximally intensive statin therapy differs between patients presenting with or without an ACS at enrollment.
Materials and Methods
Materials and Methods are available in the online-only Supplement. Table 1 presents baseline demographics, clinical characteristics, and concomitant medications in patients with ACS (n=361) and without ACS (n=678). Figure 1 describes absolute standardized differences in baseline covariates between patients with ACS and non-ACS before and after inverse probability of treatment weight adjustment. Of those presenting with ACS at baseline, 140 patients had a confirmed myocardial infarction and the remaining 221 had unstable angina. When compared with patients without ACS, those with an ACS were younger (55.9±8. 6 3 ; P<0.001) was achieved in the ACS population when compared with the non-ACS population. Changes in lumen and external elastic membrane volumes did not differ between the ACS and the non-ACS populations. At baseline, the degree of plaque calcification across the entire pullback did not differ significantly between patients with non-ACS and ACS. Table 4 summarizes a multivariable linear regression model of factors associated with changes in PAV and TAV, following inverse probability of treatment weight adjustment. A clinical presentation with an ACS was independently associated with PAV regression (β=−0.51; P=0.007) and TAV regression (β=−2.65; P=0.004). In addition, greater baseline PAV and TAV each associated with the likelihood of both PAV and TAV regression (β=−0.57; P<0.001 and β=−4.07; P<0.001, respectively). However, a higher average follow-up LDL-C level was associated with a greater likelihood of both PAV and TAV progression (β=+0.49; P<0.001 and β=+0.94; P<0.001 and P=0.03, respectively). Rosuvastatin (compared with atorvastatin) was associated with greater TAV regression (β=−2.57; P=0.005). However, there was no significant interaction between type of statin and ACS presentation on changes in TAV (P=0.15; Figure 1 ). Figure 2 shows a weighted survival curve analysis, comparing the event-free major adverse cardiovascular events (MACE) survival between patients with ACS and non-ACS. In SATURN, there were 4 cardiovascular deaths, 22 nonfatal myocardial infarctions, and 83 coronary revascularization procedures. After 24 months of maximally intensive statin therapy, 92.9% of patients with non-ACS and 90.6% of patients with ACS were free of MACE, respectively (P=0.25). Furthermore, there was no significant treatment effect on MACE (P=0.32).
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Discussion
The present analysis indicates that patients with ACS demonstrated significantly greater disease regression after maximally intensive statin therapy when compared with patients with stable coronary disease, highlighting the antiatherosclerotic benefits of long-term potent statin therapy in patients with ACS who are typically at greater cardiovascular risk. These findings provide further insight into the dynamic nature of disease-modifying therapies in patients thought to harbor the most vulnerable form of coronary disease. Across several trials evaluating serial changes in coronary atheroma volume, the baseline extent of disease was independently associated with greater plaque regression in response to disease-modifying therapies, such that those with greater baseline plaque burden invariably demonstrated the most disease regression. 24 However, despite the current multivariable analysis adjusting for the greater disease burden in ACS when compared with stable patients, an ACS clinical disposition remained independently associated with greater plaque regression. Findings of the present analysis are consistent with those of a recent meta-analysis evaluating the effect of statins on the IVUS-derived progression of coronary atherosclerosis, which uncovered a 2-fold greater decrease in coronary atheroma volume in patients with ACS when compared with those with stable coronary disease after statins. 25 An explanation of these findings may relate to underlying differences in coronary atheroma composition in patients with ACS when compared with stable patients. Pathological and imaging studies have demonstrated the coronary tree of patients with ACS to contain greater amounts of lipid-laden plaque and inflammatory infiltrate, occurring diffusely, when compared with non-ACS patients. 26 High-intensity statins possess not only potent LDL-C-lowering properties but also significant antioxidant and anti-inflammatory effects. Such properties may have rendered patients with ACS more susceptible to the antiatherosclerotic effects of these potent statins when compared with patients with chronic stable coronary disease, who more likely harbor greater degrees of less modifiable fibrocalcific plaque. Furthermore, given the extended duration of the use of highintensity statins in SATURN, this could have magnified both the delipidating and the pleiotropic actions of statins on plaque. In addition to highlighting significant coronary atheroma regression after 6 weeks of recombinant apoA-1 Milano infusions in patients with ACS, 27 2 small serial coronary IVUS studies demonstrated similar acute to short-term (6 weeks to 6 months) plaque regression when statins were administered to statin naïve patients with ACS. 28, 29 Yet, the significant degree of atheroma regression with high-intensity statins measured acutely after ACS in these studies contrasts with the lack of corresponding magnitude of disease regression measured within similar time frames in those with stable coronary disease. 30, 31 In the Early Statin Treatment in Patients With Acute Coronary Syndrome (ESTABLISH) study, moderateintensity statin therapy was associated with disease regression Table 3 at 6 months, even in individuals with low baseline LDL-C levels. However, IVUS analysis in this study was undertaken in coronary segments <10 mm in length 28 when compared with >50 mm in SATURN. Nevertheless, these previous observations further underscore the postulate that, although patients with ACS harbor high-risk coronary atheroma, their disease substrate seems to be more susceptible to plaque stabilization and regression acutely, and that this stability can be maintained during the longer term in concert with the maintenance of potent statin therapy. Although the data collected from these previous studies, including SATURN, do not establish a direct link between coronary atheroma regression and lower clinical event rates, accumulating data suggest an association between IVUS-derived coronary atheroma volume 6, 24, 32, 33 and its rate of progression, 24, 32 with incident clinical events, albeit driven largely by repeat coronary revascularization procedures.
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Despite numerous guidelines suggesting the use of highintensity statins after ACS, real-world prescribing patterns of physicians seem not to reflect these recommendations. Such findings seem common to many regions of the world. 18, 19, [34] [35] [36] Until recently, clinical guidelines tentatively recommended target LDL-C levels ≤70 mg/dL in those with established high-risk coronary disease. 11, 37 This goal may, however, be confusing for practitioners when managing patients with ACS.
No randomized controlled trials have tested the hypothesis that achieving an LDL-C of ≤70 mg/dL, irrespective of the nature and intensity of statin therapy after an ACS, is equivalent to simply the broad implementation of high-intensity statin therapy regardless of the baseline LDL-C level. Routine institution of high-intensity statin therapy, as recommended by the latest US guidelines, 10 rather than targeting a specific LDL goal, may thus be a more appropriate and more readily implemented strategy for preventing recurrent MACE after an ACS. In addition, given that the mean achieved LDL-C levels in both patient groups were 65 to 66 mg/dL, the present findings further demonstrate the antiatherosclerotic efficacy of achieving LDL-C <70 mg/dL in high-risk patients.
This was a nonprespecified post hoc analysis of SATURN, with some limitations requiring consideration. SATURN was not prospectively powered for detecting differences in MACE. Furthermore, a majority of MACE in SATURN were driven by coronary revascularization, known to be influenced by differing clinical strategies across various regions. However, all coronary revascularizations in SATURN were adjudicated by a centralized clinical events committee. Despite the inherent risk attributable to coronary revascularization per se, 38 revascularization improves the morbidity and mortality of these patients. 3 The 2.3% absolute difference in event-free survival at 24 months might have become more pronounced, had a greater number of patients been studied, and followed up for a longer duration. Plaque composition was not available for this analysis, which may have provided further mechanistic insight into the reasons why plaque regression was greater in patients with ACS when compared with non-ACS patients. A recent prespecified post hoc analysis of serial plaque composition changes in SATURN uncovered that atheroma regression to high-intensity statins was mediated mostly by significant reductions in the fibrofatty (lipidic) component of plaque. 39 However, the serial radiofrequency backscatter analysis of plaque composition still possesses inherent limitations and warrants further investigation. 40 Although sophisticated statistical techniques were used to account for baseline differences between the ACS and non-ACS groups, propensity-weighting may not have eliminated the effects of unknown confounding variables that could have biased this analysis. For example, patients with ACS could have a greater tendency for behavior modification when compared with their stable coronary disease counterparts. Behavioral modification data (ie, smoking cessation, exercise, and dietary modification) and its potential affect on disease progression were not collected in SATURN. Furthermore, we cannot exclude a type-1 error rate because of the multiple statistical tests performed, and no further adjustments were made on the large number of multiple comparisons.
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